Cytodyn Inc (CYDY)

[B52T38]

Question for the Board:

If I understand how CYDY's current COVID trials are structured, the daily/weekly trial results are not even known by our CEO and our other doctors and board members. However, they do have access to the raw data on each patient, the results of each's blood work, data that might indicate if the patient received Leronlimab. Correct?

If so, then they should have a pretty good idea (roughly 80% chance, just to put a number on it) if Leronlimab is at least meeting the 50% success rate against COVID 19, a threshold established by the FDA. Correct?

And if so...then wouldn't this distribution agreement with American Regent be a REALLY GOOD indicator of success with Leronlimab in the COVID trials? I mean, if our CEO and our docs didn't see the kind of data they needed to see, why would they go through all this effort and expense to sign a distribution deal SPECIFICALLY FOR making Leronlimab available? This is NOT a deal to distribute Leronlimab for HIV/AIDS, it's specifically for COVID 19.

In short, isn't this announcement a REALLY SOLID indicator of Leronlimab success in the trials?